ESPR (Esperion Therapeutics) Tariff Resilience Score: 7/10 (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ESPR Esperion Therapeutics Inc ESPR
62 GF Score
Price $3.18
GF Value $2.30
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Esperion Therapeutics Tariff Resilience Score?

Esperion Therapeutics ESPR -0.31% 62 Tariff Resilience Score is 7 as of Aug. 04, 2026. GuruFocus rates ESPR with a GF Score™ of 62/100 and a GF Value™ of $2.30 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,027 Drug Manufacturers companies, Esperion Therapeutics ranks better than 97.08% on this metric.

Esperion Therapeutics has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Esperion Therapeutics has Esperion Therapeutics Inc has limited exposure to tariffs as a pharmaceutical company. Its supply chain is less affected by tariffs, and it has some pricing power. Historical impacts have been minimal.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Esperion Therapeutics might have Highly Resilient.

Esperion Therapeutics  (NAS:ESPR) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Esperion Therapeutics Tariff Resilience Score Related Terms

ESPR vs AMPH, NIKA, BIOA: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Esperion Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Esperion Therapeutics Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Esperion Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Esperion Therapeutics's Tariff Resilience Score falls into.


ESPR
62GF Score
Esperion Therapeutics Inc ESPR
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Esperion Therapeutics (ESPR) has a Tariff Resilience Score of 7 as of Aug. 04, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Esperion Therapeutics ranks #30 out of 1027 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Esperion Therapeutics' Tariff Resilience Score too high?
Esperion Therapeutics' current Tariff Resilience Score is 7. Based on the distribution chart, Esperion Therapeutics ranks #30 out of 1027 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Esperion Therapeutics has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Esperion Therapeutics' Tariff Resilience Score compare to AMPH and NIKA?
According to the Drug Manufacturers industry distribution chart, Esperion Therapeutics ranks #30 out of 1027 companies for Tariff Resilience Score. This places Esperion Therapeutics in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Esperion Therapeutics's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Esperion Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Esperion Therapeutics (ESPR) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.30, compared to a current price of $3.18 — trading 38.3% above its estimated fair value. The current Tariff Resilience Score is 7. Esperion Therapeutics' overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Esperion Therapeutics (ESPR), the current Tariff Resilience Score is 7 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Esperion Therapeutics (ESPR) Overvalued in 2026?

Based on GuruFocus' analysis, Esperion Therapeutics stock appears to be overvalued. The current stock price of $3.18 is trading 38.3% above its estimated GF Value™ of $2.30. GuruFocus considers Esperion Therapeutics to be Significantly Overvalued.

Key valuation signals for ESPR:

  • Tariff Resilience Score: 7
  • GF Value™: $2.30 vs. price of $3.18 (38.3% above fair value)
  • GF Score™: 62/100 with 6 warning signs

No single metric tells the full story. See the ESPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Esperion Therapeutics Business Description

Other Exchanges 0IIM:UK0ET:Germany
Address 3891 Ranchero Drive, Suite 150, Ann Arbor, MI, USA, 48108
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
62GF Score

Get the complete analysis for ESPR

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.18
Price
$2.30
GF Value